Pre-market: CHM.AX stock down 20% to A$0.002 on ASX: watch catalysts ahead

CHM.AX stock plunged 20.0% pre-market to A$0.002 on the ASX after heavy selling into low liquidity. We saw 600,000 shares trade versus a 50-day average of 5,804,285, a sign that small orders can move the price. With an upcoming earnings announcement on 26 Feb 2026 and clinical trial readouts pending, traders are re-pricing risk for Chimeric Therapeutics Limited (CHM.AX) in Australia.

Pre-market price action and volume

CHM.AX stock opened at A$0.002, down A$0.0005 from the previous close of A$0.0025. The session range was A$0.002–A$0.002 and year range is A$0.002–A$0.009. Reported volume was 600,000 shares versus an average volume of 5,804,285, giving a relative volume of 0.11. Low liquidity magnified the fall and left the share price sitting at its year low support.

Drivers: news, calendar and sector context

There is no single public catalyst tied to today’s drop. Market participants pointed to upcoming corporate events including an earnings announcement scheduled for 26 Feb 2026 and ongoing phase I clinical programmes. We also note healthcare sector momentum is muted, which can reduce bid depth for smaller biotech names. For benchmarking and peer comparisons see recent market pages on Investing.com for Chimeric source and a profile comparison source.

Fundamentals and valuation snapshot

Chimeric Therapeutics Limited (CHM.AX) is a clinical-stage biotechnology company listed on the ASX. Key metrics: EPS -A$0.01, PE -0.20, market cap A$8,837,407, shares outstanding 4,418,707,619. Price-to-sales is 0.97, price-to-book 1.72, and cash per share A$0.0034. The company spends heavily on R&D (R&D to revenue > 1.01x), which drives negative operating cash flow per share A$-0.00293 and a current ratio of 0.72. These metrics explain weak valuation relative to larger healthcare peers.

Technicals and trading setup for CHM.AX stock

On technicals CHM.AX shows weakness: RSI 39.73, ADX 16.50 (no clear trend), 50-day average A$0.00267 and 200-day average A$0.00352. On-balance volume sits at 29,819,783 reflecting past issuance and trading. The combination of low price, thin liquidity and a tight trading range increases short-term volatility. Immediate support sits at A$0.002; a break below could limit bids, while resistance near the year high of A$0.009 is distant.

Meyka AI grade and model forecast

Meyka AI rates CHM.AX with a score out of 100: 66.18 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly level of A$0.010 versus the current price A$0.002, implying an upside of 400.00%. Forecasts are model-based projections and not guarantees. As an AI-powered market analysis platform, Meyka AI flags high idiosyncratic risk tied to clinical outcomes and funding.

Risks and opportunities for investors

Primary risks: trial failures, dilution from capital raises, and very low liquidity that amplifies moves. Secondary risks: negative EPS trajectory and weak current ratio. Opportunities: positive clinical readouts or licensing deals could reopen upside quickly. Our view: CHM.AX stock suits speculative traders who can tolerate volatility and potential dilution, not income or low-risk portfolios. See our Meyka stock page for CHM.AX for data and alerts source.

Final Thoughts

CHM.AX stock ranks among the top pre-market losers after a 20.0% decline to A$0.002 on ASX amid thin liquidity and event risk. Fundamentals show negative EPS A$-0.01, tight cash per share A$0.0034, and a market cap of A$8,837,407, which explains conservative market valuations. Our Meyka AI forecast model projects a quarterly level of A$0.010, implying +400.00% from the current price, but this is a model projection and not a guarantee. Near term, watch volume, the upcoming 26 Feb 2026 earnings date and any clinical updates; a positive readout could drive a rapid re-rating while a failed trial or equity raise would likely pressure the share price further. For traders we recommend strict position sizing and an exit plan because CHM.AX’s low liquidity magnifies both gains and losses.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.